Obesidad, insulinorresistencia, dislipemia e hipertensión: síndrome dismetabólicoPredisposing factors for type 2 diabetes and cardiovascular risk in childhood. G. Marañón. La obesidad desde el punto de vista de su pronóstico y tratamiento Consenso SEED O’ para la evaluacion del sobrepeso y la obesidad y el. La dislipemia, hipertensión, insulinorresistencia, alteración hidrocarbonada y obesidad son potentes factores de riesgo de la enfermedad cardiovascular en el .
| Author: | Daihn Volmaran |
| Country: | Thailand |
| Language: | English (Spanish) |
| Genre: | Science |
| Published (Last): | 26 December 2005 |
| Pages: | 151 |
| PDF File Size: | 20.92 Mb |
| ePub File Size: | 8.51 Mb |
| ISBN: | 388-2-67048-881-7 |
| Downloads: | 53920 |
| Price: | Free* [*Free Regsitration Required] |
| Uploader: | Kegore |
The metabolic syndrome MS is receiving considerable attention from the health sector, not only because of the number of patients suffering from this disorder, but also because of its association with a number of metabolic disturbances type 2 diabetes mellitus, cardiovascular diseases, etc.
The diagnostic criteria, defined by various committees and international organizations, are alterations in glucose homeostasis, insulin resistance, abdominal obesity, impaired lipid profile, and hypertension.
Several methods have been devised to assess insulin resistance: Patients with MS often show signs of hyperinsulinemia, which has metabolic implications affecting glucose and lipid metabolism in various organs such as adipose tissue, liver, and skeletal muscle. Metabolic syndrome, insulin resistance and tissue metabolism. Patients with MS often show signs of hyperinsulinemia, which has metabolic implications affecting glucose and lipid metabolism in various organs such as adipose tissue, liver, and skeletal muscle.
Sven Med Tidskr, 5pp. Nuevos problemas de las secreciones internas, pp. Diabetes, 37pp. The central role of dietary fat not carbohydrate, in the insulin resistance syndrome.
Curr Opin Lipidol, 8pp. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest, 92pp.
Pathophysiology of insulin resistance in human disease. Physiol Rev, 75pp. Do high carbohydrate diets prevent the development or attenuate the manifestations or both of syndrome X?
A viewpoint strongly against. Control of energy homeostasis and insulin action by adipocyte hormones: Curr Insulinorresisstencia Lipidol, 13pp. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: Provisional report of a WHO consultation. Diabetes Med, 15pp. JAMA,pp. Consenso SEED O’ para la evaluacion del sobrepeso y la obesidad y el establecimiento de criterios de intervencion terapeutica.
Med Clin, 15pp. Abdominal adipose tissue distribution obesity and of cardiovascular disease and death: Br Med J,pp. Risk factors associated with obesity: Ann Endocrinol, 6pp. Interrelationship between serum lipid profile, serum hormones and other components of the metabolic syndrome. J Physiol Biochem, 58pp. Code for Dysmetabolic Syndrome X. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.
The Metabolic Syndrome in Spain. El insulinorreskstencia metabolico en su 80 aniversario.
Resistencia a la insulina y su implicacion en multiples factores de riesgo asociados a diabetes insulinorresisyencia 2. Med Clin Barc, pp. Lancet, 1pp.
Forearm metabolism in obesity and its response to intra-arterial insulin. Evidence for adaptive hyperinsulinismus. Lancet, 2pp.
Role of insulin in regulation of lipoprotein metabolism in diabetes. Diab Metabol Rev, 4pp. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease.
Diabetes Care, 14pp.
Is insulin resistance linked to hypertension?. Clin Exp Pharmacol Physiol, 25pp. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: Diabetologia, 45pp. Am J Physiol,pp. Quantitative estimation of insulin sensitivity.
Am J Physiol, 23pp. Glucose insulin and somatostatin infusions for measurement of in vivo insulin resistance. J Clin Endocrinol Metab, 45pp. Estimates in vivo insulin action in man: J Clin Endocrinol Metab, 68pp. Diabetologia, 28pp. Continuous infusion of glucose with model assessment: Nuevo panorama para el entendimiento de los vinculos moleculares entre la obesidad y la diabetes tipo 2.
Síndrome metabólico, resistencia a la insulina y metabolismo tisular | Endocrinología y Nutrición
Rev Invest Clin, 53pp. Anales Del Sist San Nav, 25pp. Nutr Soc, 56pp.
Effect of feeding and obesity on lipoprotein lipase activity, immunoreactive protein, and messenger RNA levels in human adipose tissue. Clin Inves, 84pp. Adipose tissue metabolism in obesity: Metabolism, 41pp. The missing link with obesity?.
Nature,pp. Effect of fatty acids on glucose production and utilization in man. Journal of Clinical Investigation, 72pp. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest, 93pp. Genetic and clinical implications. Diabetes, 44pp. Br J Nutr, 83pp. Science,pp. Papel del factor de necrosis tumoral en el control de las reservas grasas y la obesidad.
The expression of tumor necrosis factor in human adipose tissue: J Clin Invest, 95pp. J Clin Invest, 97pp. Tumor necrosis factor alpha: Diabetes, 43pp. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF and obesity induced insulin resistance. Diabetes, 45pp. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab, 82pp. Subcutaneous adipose tissue expression of tumor necrosis factor-alpha is not associated with whole body insulin resistance in obese nondiabetic or in type-2 diabetic subjects.
Eur J Clin Invest, 30pp. Novel modulator for endothelial adhesion molecular. Adipocyte-derived plasma protein adiponectin.
There was a problem providing the content you requested
Circulation,pp. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun,insulinorresiztencia. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol, 20pp. Hypoadiponectinemia in obesity and type 2 diabetes: Endocrinol Metab, 86pp. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.
Nat Med, 7pp.